Drugs / RSV 6120/∆NS2/1030s
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03387137 | Oct 2017 → Nov 2019 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV 6120/∆NS2/1030s | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387137 ↗ |
| Known as | RSV/6120/ΔNS2/1030s | “RSV/6120/ΔNS2/1030s is a cDNA-derived live-vaccine candidate attenuated by deletion of the interferon antagonist NS2 gene and the genetically stabilized 1030s missense...” PMID 37493269 ↗ Feb 2024 |
| Modality | Vaccine | “RSV/6120/ΔNS2/1030s is a cDNA-derived live-vaccine candidate attenuated by deletion of the interferon antagonist NS2 gene and the genetically stabilized 1030s missense...” PMID 37493269 ↗ Feb 2024 |
| Route | Intranasal | “A single intranasal dose of RSV/6120/ΔNS2/1030s was evaluated” PMID 37493269 ↗ Feb 2024 |